Welcome to EnVivo Pharmaceuticals

		Home \| Company \| Our Team \| Programs \| Publications \| News & Events

EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, and Schizophrenia. The company’s lead programs include a Nicotinic Alpha 7 Acetylcholine Receptor Agonist Program for cognitive enhancement in Alzheimer’s disease and Schizophrenia, a Histone Deacetylase (HDAC) Inhibitor Program for cognitive enhancement in Alzheimer’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phosphodiesterase-10 (PDE10) Program for Schizophrenia.

EnVivo News & Events

	WATERTOWN, Mass., January 19, 2010 – EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund research as part of the foundation’s Therapeutics Development Initiative that seeks new treatments for Parkinson’s disease.



	WATERTOWN, Mass., January 5, 2010 – EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.